Chloroquine
As of the edition of 20 October 2026, Chloroquine is a small molecule: marketed, first approved in 1951 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Aralen
- First approved
- 1 June 1951 (ES)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- Sanofi; 2 holders in all
- Registered trials
- 113, 20 stopped early
- Disease areas
- Infections; Cancer; Lungs and airways; Immune system; Blood and lymph; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 20 | 18 | 0 | 0 |
| Phase 1 | 15 | 10 | 0 | 3 |
| Phase 2 | 27 | 13 | 3 | 9 |
| Phase 3 | 27 | 17 | 1 | 7 |
| Phase 4 | 24 | 20 | 2 | 1 |
| All trials | 113 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Applicant and Lead sponsor of trials | 2018 to now |